Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma. Issue 10 (8th September 2017)

• Record Type: Journal Article
• Authors: Charoensri, Suranut; Sriphrapradang, Chutintorn; Nimitphong, Hataikarn
• Is Part Of: Clinical case reports. Volume 5:Issue 10(2017)
• Page Start: 1706
• Page End: 1711
• Publication Date: 2017-09-08
• Subjects: Coma -- hypothyroidism -- myxedema -- oral administration -- thyroxine; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.1131
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: High‐dose intravenous thyroxine (T4) is the preferable treatment for myxedema coma. We describe the clinical course of a 69‐year‐old man who presented with myxedema coma and received oral levothyroxine (LT4) therapy (1 mg) in a split dose. This suggests split high‐dose oral LT4 as a therapeutic option in myxedema coma. Abstract : High‐dose intravenous thyroxine (T4) is the preferable treatment for myxedema coma. We describe the clinical course of a 69‐year‐old man who presented with myxedema coma and received oral levothyroxine (LT4) therapy (1 mg) in a split dose. This suggests split high‐dose oral LT4 as a therapeutic option in myxedema coma.